A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases
Journal of Molecular Pathology · 2021
DOI: 10.3390/jmp2010001 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Molecular Pathology, 2021. Verfasst von Salvatore Caponnetto und 9 weiteren Autor:innen. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of the efficacy of different-generation EGFR-tyrosine kinase inhibitors (TKI) on BMs from NSCLC are currently limited. We identified studies comparing different EGFR-TKIs for NSCLC through Pubmed literature search and selected those with neurological outcome data. By two retrospective analyses, Erlotinib showed longer neurological time-to-progression (30 months vs. 15.8 months, P = 0.024) and reduced the risk of central nervous system (CNS) progression (Hazard Ratio (HR) 0.25; 95% CI, 0.08–0.81; P = 0.021) compared to Gefitinib. In a phase 2b randomized trial, 16% of patients with BMs had a similar Progression Free Survival (PFS) (HR 0.76, 95% CI 0.41–1.44) or Overall Survival (OS) (HR 1.16, 95% CI 0.61–2.21) with Afatinib versus Gefitinib; a lower risk of developing subsequent BMs with Afatinib than Gefitinib (HR 0.49; 95% CI 0.34–0.71; P < 0.001) was reported by a retrospective study. A randomized phase 3 trial proved that patients with BMs treated with Osimertinib had longer PFS (HR 0.47, 95% CI 0.30–0.74) and OS (HR 0.79, 95% CI 0.61–1.01) than with Gefitinib, and lower incidence of CNS progression (6% vs. 15%, respectively). Although there is limited evidence, differences in CNS activity may exist between EGFR-TKIs.
Zitieren
APA
Caponnetto, S., Cantale, O., Friedlaender, A., Gomes, F., Daryanani, S., Gelibter, A., Cortellini, A., Giuffrida, D., Addeo, A., & Banna, G. L. (2021). A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases. Journal of Molecular Pathology. https://doi.org/10.3390/jmp2010001
Vancouver
Caponnetto S, Cantale O, Friedlaender A, Gomes F, Daryanani S, Gelibter A, et al. A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases. Journal of Molecular Pathology. 2021. doi:10.3390/jmp2010001
BibTeX
@article{Caponnetto2021,
author = {Caponnetto, Salvatore and Cantale, Ornella and Friedlaender, Alex and Gomes, Fabio and Daryanani, Sunil and Gelibter, Alain and Cortellini, Alessio and Giuffrida, Dario and Addeo, Alfredo and Banna, Giuseppe Luigi},
title = {A Comparison Between First-, Second- and Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Non-Small-Cell Lung Cancer and Brain Metastases},
journal = {Journal of Molecular Pathology},
year = {2021},
doi = {10.3390/jmp2010001}
}
EUVIMED